Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Net Margin (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Net Margin for 13 consecutive years, with 6237.29% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 21635.0% to 6237.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8486.84% through Dec 2025, down 137345.0% year-over-year, with the annual reading at 10579.84% for FY2025, 782025.0% down from the prior year.
  • Net Margin hit 6237.29% in Q4 2025 for Vistagen Therapeutics, up from 7525.97% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 90900.0% in Q1 2025 to a low of 42789.74% in Q1 2022.
  • Historically, Net Margin has averaged 2354.04% across 5 years, with a median of 5913.21% in 2024.
  • Biggest five-year swings in Net Margin: crashed -3610196bps in 2022 and later soared 9670549bps in 2025.
  • Year by year, Net Margin stood at 3000.56% in 2021, then tumbled by -81bps to 5422.89% in 2022, then surged by 72bps to 1545.01% in 2023, then crashed by -290bps to 6020.94% in 2024, then fell by -4bps to 6237.29% in 2025.
  • Business Quant data shows Net Margin for VTGN at 6237.29% in Q4 2025, 7525.97% in Q3 2025, and 6186.48% in Q2 2025.